Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 9:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 362 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Reference Product Clear all
Completed Phase 1 Interventional

Bioequivalence of Adapalene Topical Gel in Patients With Acne Vulgaris

NCT01182636
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene, Differin®, Placebo
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
12 Years to 40 Years
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
20
States / cities
Little Rock, Arkansas • Los Angeles, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2010 · Synced Oct 19, 2026, 9:37 PM EDT
Completed Phase 3 Interventional Results available

Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma

NCT03976102
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
DRL_RI (Proposed rituximab biosimilar), MabThera®
Biological · Other
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
Whittier, California • Bethesda, Maryland • Knoxville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2024 · Synced Oct 19, 2026, 9:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess The Relative Bioavailability of New Tablet Formulations of GSK1265744 in Healthy Adult Subjects

NCT02059031
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK1265744 Reference formulation, GSK1265744 New formulation 1, GSK1265744 New formulation 2
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2014 · Synced Oct 19, 2026, 9:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Fasting Conditions.

NCT01260922
View directory record Official record
Conditions
Healthy
Interventions
Donepezil Hydrochloride, Aricept®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
East Grand Forks, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 21, 2011 · Synced Oct 19, 2026, 9:37 PM EDT
Completed Not applicable Interventional Results available

Value of Technology to Transfer Discharge Information

NCT00101868
View directory record Official record
Conditions
Information Dissemination, Interprofessional Relations
Interventions
Discharge communication software, Usual care discharge process
Device · Other
Lead sponsor
Agency for Healthcare Research and Quality (AHRQ)
Federal
Eligibility
18 Years and older
Enrollment
631 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated May 15, 2012 · Synced Oct 19, 2026, 9:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Oxycodone Hydrochloride 15 mg Tablets and Roxicodone™ 15 mg Tablets

NCT00853320
View directory record Official record
Conditions
Healthy
Interventions
Oxycodone hydrochloride tablet 15 mg, Roxicodone™ tablet 15 mg
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 19, 2016 · Synced Oct 19, 2026, 9:37 PM EDT
Completed Not applicable Interventional Results available

ABSORB III Randomized Controlled Trial (RCT)

NCT01751906
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
Interventions
Absorb BVS, XIENCE
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,008 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
190
States / cities
Birmingham, Alabama • Fairhope, Alabama • Montgomery, Alabama + 145 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Oct 19, 2026, 9:37 PM EDT
Terminated Phase 3 Interventional

A BE Study to Compare Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg and QVAR® 40 mcg, Inhalation Aerosol

NCT03562949
View directory record Official record
Conditions
Asthma
Interventions
Test Product, Reference Product, Placebo
Drug
Lead sponsor
Amneal Ireland Limited
Industry
Eligibility
18 Years to 70 Years
Enrollment
761 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
12
States / cities
Huntington Beach, California • Los Angeles, California • Doral, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 19, 2026, 9:37 PM EDT
Active, not recruiting Not applicable Interventional

Electrical Neuromodulation for Modifying Spinal Network Involved in Spasticity

NCT07792616
View directory record Official record
Conditions
Spinal Cord Injuries (Complete and Incomplete), Spinal Cord Injury, Spinal Cord Injury Cervical, Spinal Cord Injury Thoracic, Spinal Cord Injuries, Spasticity, Spasm, Muscle Spasticity, Muscle Hypertonia, Muscle Spasm
Interventions
Transcutaneous spinal stimulation at 30 Hz, Transcutaneous spinal stimulation at 75 Hz, Tizanidine, Baclofen, Placebo
Other · Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 19, 2026, 9:37 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

IV Iron Safety: Evaluation of Iron Species in Healthy Subjects

NCT02399449
View directory record Official record
Conditions
Anemia
Interventions
Brand sodium ferric gluconate, Generic sodium ferric gluconate
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 19, 2026, 9:37 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

NCT03972488
View directory record Official record
Conditions
Gastro-enteropancreatic Neuroendocrine Tumor
Interventions
Lutathera, 30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot), 2.5% Lys-Arg sterile amino acid solution, High dose 60 mg octreotide long-acting repeatable
Drug
Lead sponsor
Advanced Accelerator Applications
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
6
States / cities
New Haven, Connecticut • Tampa, Florida • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 19, 2026, 9:37 PM EDT
Completed Phase 1 Interventional Results available

Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma

NCT02260492
View directory record Official record
Conditions
Asthma
Interventions
OT329 (combination of fluticasone propionate and salmeterol xinafoate), Advair Diskus (combination of fluticasone propionate and salmeterol xinafoate), Placebo
Drug
Lead sponsor
Oriel Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
879 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
47
States / cities
Goodyear, Arizona • Tempe, Arizona • Anaheim, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2017 · Synced Oct 19, 2026, 9:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Two Vonoprazan Orally Disintegrating Tablet Formulations Administered Without Water or Mixed With Water and Administered Via a Syringe Relative to the Vonoprazan Tablet in Healthy Participants

NCT06831344
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Vonoprazan ODT-1 or ODT-2 without Water, Vonoprazan ODT-1 or ODT-2 with Water, Vonoprazan (Reference)
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 19, 2026, 9:37 PM EDT
Completed Phase 3 Interventional Results available

Pilot Study Comparing Hypnotherapy and Gabapentin for Hot Flashes.

NCT00711529
View directory record Official record
Conditions
Breast Cancer, Hot Flashes
Interventions
Hypnotherapy, gabapentin
Behavioral · Drug
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 19, 2026, 9:37 PM EDT
Completed Not applicable Interventional

Nicotine Pharmacokinetics and Subjective Effects of Oral Nicotine Products Relative to Smokeless Tobacco in Adult Users

NCT06691386
View directory record Official record
Conditions
Tobacco Use
Interventions
Test Product A, Test Product B, Test Product C, Test Product D, Test Product E, Reference Product F: Subjects' OBMST
Other
Lead sponsor
Altria Client Services LLC
Industry
Eligibility
22 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Bentonville, Arkansas • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 17, 2025 · Synced Oct 19, 2026, 9:37 PM EDT
Completed Phase 2 Interventional

A Safety Study of 188-0551 Spray Versus Reference Listed Drug (RLD) in Adult Subjects With Plaque Psoriasis

NCT04080206
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
188-0551 Spray, RLD
Drug
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Scottsdale, Arizona • Thousand Oaks, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Oct 19, 2026, 9:37 PM EDT
Completed Phase 3 Interventional

BE Study of Albuterol Sulfate Inhalation Aerosol 90 mcg Per Actuation in Patients With Stable Mild Asthma

NCT06154304
View directory record Official record
Conditions
Bronchial Asthma
Interventions
Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation), Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1, Ventolin HFA, 90 Mcg/Inh Inhalation Aerosol_#2, Placebo
Drug
Lead sponsor
Cipla Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Medford, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 19, 2026, 9:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Clarithromycin 500 mg Extended Release Tablets Under Fasting Conditions

NCT00840411
View directory record Official record
Conditions
Healthy
Interventions
Clarithromycin ER 500 mg tablets, BIAXIN® XL 500 mg tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 19, 2026, 9:37 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis

NCT02611830
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Vedolizumab 300 mg IV, Placebo IV, Vedolizumab 108 mg SC, Placebo SC
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
28
States / cities
Little Rock, Arkansas • Wheat Ridge, Colorado • Middletown, Connecticut + 25 more
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Oct 19, 2026, 9:37 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Equivalence of GDC-229 and Metronidazole Vaginal Gel 0.75% in the Treatment of Bacterial Vaginosis

NCT03091777
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
GDC-229, Metronidazole Vaginal Gel 0.75%, Placebo
Drug
Lead sponsor
Balmoral Medical company
Industry
Eligibility
18 Years and older · Female only
Enrollment
871 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 7, 2020 · Synced Oct 19, 2026, 9:37 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Study of Virtually Supervised Mouth Rinses and Flossing

NCT05600231
View directory record Official record
Conditions
Healthy
Interventions
LISTERINE COOL MINT Antiseptic Mouthwash, LISTERINE COOL MINT ZERO Alcohol Mouthwash, Reach Unflavored Waxed Dental Floss, Colgate Cavity Protection Toothpaste
Other
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
18 Years and older
Enrollment
284 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 19, 2026, 9:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Lansoprazole 30 mg DR Capsule Fasting Replicate Sprinkle Study

NCT01046253
View directory record Official record
Conditions
Healthy
Interventions
Lansoprazole, Prevacid®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 8, 2010 · Synced Oct 19, 2026, 9:37 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Effect of of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base (Sun Pharmaceuticals Industries Limited)

NCT03528577
View directory record Official record
Conditions
Asthma
Interventions
Zero-dose, 90 mcg of PROAIR® HFA, 180 mcg of 90 mcg of PROAIR® HFA, 90 mcg of albuterol sulfate inhalation aerosol
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
8
States / cities
Miami Lakes, Florida • Bethesda, Maryland • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 19, 2026, 9:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A 26-week Extension of the ZRHR-ERS-09-US Study Evaluating Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2

NCT02649556
View directory record Official record
Conditions
Smoking
Interventions
THS 2.2, CC
Other
Lead sponsor
Philip Morris Products S.A.
Industry
Eligibility
30 Years and older
Enrollment
672 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
19
States / cities
Tempe, Arizona • Clearwater, Florida • Daytona Beach, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2020 · Synced Oct 19, 2026, 9:37 PM EDT